Neamine Or Derivative (e.g., Neomycin A, Etc.) Patents (Class 536/16.6)
-
Publication number: 20140323422Abstract: The invention relates to anionic conjugates of glycosylated bacterial metabolites that may be used to mimic the structure and/or activity of the anionic bioactive molecules known as glycosaminoglycans (GAGs). The invention also relates to processes for the preparation of the conjugates. Such conjugates are useful in the prophylaxis and/or treatment of disease conditions and in particular chronic disease conditions such as inflammatory (including allergic) diseases, metastatic cancers and infection by pathogenic agents including bacteria, viruses or parasites.Type: ApplicationFiled: July 10, 2014Publication date: October 30, 2014Inventors: Warren Charles KETT, Yugang CHEN
-
Patent number: 8729035Abstract: This invention concerns compounds with the formula: in which: R1?OH or NH2; OR2, OR3, OR4 and OR5 are alcohol, ether, ester, carbonate, carbamate, sulphonate or sulphamate groups; and if R5?H if R2?R3?R4, then R2, R3 and R4?H; if R2?H, then R3?H and R4?H; if R3?H, then R2?H and R4?H; if R4?H, then R2?H and R3?H; if R5?H if R2=H, then R3?H and R4?H; if R3?H, then R2?H and R4?H; if R4?H, then R2?H and R3?H, their use as antibiotic agents and the process for synthesizing them.Type: GrantFiled: January 22, 2009Date of Patent: May 20, 2014Assignee: Universite Joseph FourierInventors: Jean-Luc Decout, Isabelle Baussanne, Jerome Desire, Jean-Marc Paris
-
Publication number: 20140038914Abstract: This invention relates to a compound of Formula 1A: or a pharmaceutically acceptable salt thereof; wherein R1 to R4, R7, R9 to R12 and Y are as defined herein. The invention further relates to pharmaceutical composition comprising said compound or a pharmaceutically acceptable salt thereof; and method of using same for reducing or reversing bacterial resistance to at least one aminoglycoside antibiotic.Type: ApplicationFiled: January 17, 2012Publication date: February 6, 2014Applicant: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITYInventors: Karine Auclair, Kenward Vong
-
Patent number: 8633303Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).Type: GrantFiled: June 21, 2011Date of Patent: January 21, 2014Assignee: Glycomimetics, Inc.Inventors: John L. Magnani, John T. Patton, Jr., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst
-
Patent number: 8338386Abstract: The present invention relates to the prevention/treatment of ichthyosis vulgaris (IV), atopy and potentially other disorders associated with loss-of-function mutations in the filaggrin gene sequence. The prevention/therapy is based on the use of agents which enable the host's translational machinery to read through a nonsense mutation found in a mutant allele of the filaggrin gene.Type: GrantFiled: January 17, 2007Date of Patent: December 25, 2012Assignee: University Court of the University of DundeeInventors: William Henry Irwin McLean, Frances Jane Dorothy Smith
-
Patent number: 7989601Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).Type: GrantFiled: April 20, 2010Date of Patent: August 2, 2011Assignee: GlycoMimetics, Inc.Inventors: John L. Magnani, John T. Patton, Jr., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst
-
Publication number: 20110118202Abstract: The dimerization of HIV RNA is a key step in the virus replication cycle. Based on RNA DIS crystal structures, a novel kind of compounds, dimeric or not, based on neamine was designed and synthesized. Biological studies showed that such compounds bind and interfere with the targeted RNA sequence, opening a new anti-HIV approach. The crystal structures and bio-chemical experiments showed that the DIS of HIV-1 genomic RNA is a target for new anti-HIV drugs and that those drugs could be derived from aminoglycosides. The results revealed that binding of aminoglycosides to the DIS is specific regarding both the aminoglycoside family and the RNA subtype.Type: ApplicationFiled: March 23, 2007Publication date: May 19, 2011Inventors: Patrick Pale, Jean-Marc Weibel, Anne Bodlenner, Roland Marquet, Jean-Cristophe Paillart, Philippe Dumas, Eric Ennifar, Philippe Walter
-
Publication number: 20100311680Abstract: This invention concerns compounds with the formula: in which: R1=OH or NH2; OR2, OR3, OR4 and OR5 are alcohol, ether, ester, carbonate, carbamate, sulphonate or sulphamate groups; and if R5=H if R2=R3=R4, then R2, R3 and R4?H; if R2=H, then R3?H and R4?H; if R3=H, then R2?H and R4?H; if R4=H, then R2?H and R3?H; if R5?H if R2=H, then R3?H and R4?H; if R3=H, then R2?H and R4?H; if R4=H, then R2?H and R3?H, their use as antibiotic agents and the process for synthesising them.Type: ApplicationFiled: January 22, 2009Publication date: December 9, 2010Applicant: Universite Joseph FourierInventors: Jean-Luc Decout, Isabelle Baussane, Jerome Desire, Jean-Marc Paris
-
Patent number: 7728117Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).Type: GrantFiled: September 1, 2006Date of Patent: June 1, 2010Assignee: GlycoMimetics, Inc.Inventors: John L. Magnani, John T. Patton, Jr., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst
-
Patent number: 7626005Abstract: The present invention relates to novel inhibitors of aminoglycoside 6?-N-acetyltransferases, more specifically, AAC(6?)-li and AAC(6?)-ly, as well as compositions and uses thereof. Furthermore, the present invention relates to synthetic methodologies for preparing the inhibitors of aminoglycoside 6?-N-acetyltransferases.Type: GrantFiled: February 21, 2006Date of Patent: December 1, 2009Assignee: McGill UniversityInventors: Karine Auclair, Feng Gao, Xuxu Yan
-
Patent number: 7514404Abstract: The present invention relates to methods and compositions pertaining to conjugates composed of a peptide nucleic acid (PNA) moiety and a neamine derivative moiety. Methods for using such conjugates for modulating the activity of a target nucleic acid molecule and for preventing or treating a disease associated with an aberrant nucleic acid molecule are also provided.Type: GrantFiled: December 6, 2004Date of Patent: April 7, 2009Assignee: University of Medicine & Dentistry of New JerseyInventors: Jean-Luc Decout, Virendra N. Pandey, Emmanuel Riguet
-
Patent number: 7476656Abstract: The invention relates to target-associative tags incorporating cysteamine as the target-associative moiety. The invention further relates to a method for producing a target-associative tag by addition of cysteamine as the target-associative moiety to another molecule or entity having a property or properties useful in discriminating or selecting between members of a set, where such properties could include, for example, fluorescence, mass, affinity, reactivity, size, absorbance, magnetism, subatomic spin characteristics, or an ability to associate specifically or preferentially with certain structures. The invention further relates to a method for analyzing, identifying, or purifying phosphorylated proteins or phosphorylated protein fragments using a tag having the properties of both fluorescence and affinity.Type: GrantFiled: November 9, 2004Date of Patent: January 13, 2009Assignee: University of Florida Research Foundation, Inc.Inventors: Stanley Merewyn Stevens, Jr., Alfred Y K Chung
-
Patent number: 7371733Abstract: The invention relates to novel paranmycin compounds that have activity against gram positive and gram negative bacteria, preferably bacteria that are resistant to other antibiotics.Type: GrantFiled: March 20, 2006Date of Patent: May 13, 2008Assignee: Utah State UniversityInventor: Cheng-Wei Tom Chang
-
Patent number: 7244712Abstract: The present invention relates to aminoglycoside compounds having antibiotic activity. Moreover, the present invention relates to L-aminoglycoside compounds and diastereomers thereof which posses antibiotic activity and are not susceptible to development of resistant bacterial strains. The present invention also relates to methods of treatment and pharmaceutical compositions that utilize or comprise one or more of aminoglycoside compounds provided by the invention.Type: GrantFiled: September 14, 2004Date of Patent: July 17, 2007Assignee: President and Fellows of Harvard CollegeInventor: Robert R. Rando
-
Patent number: 6967242Abstract: The present invention is directed to analogs of aminoglycoside compounds of the class having a glycosylated 2-deoxystreptamine (2-DOS) ring as well as their preparation and use as prophylactic or therapeutics against microbial infection. Compounds of the invention comprises at least one aryl, heteroaryl, substituted aryl or substituted heteroaryl group in place of a glycosyl group attached to the 2-deoxystreptamine ring.Type: GrantFiled: November 19, 2002Date of Patent: November 22, 2005Assignee: ISIS Pharmaceuticals, Inc.Inventors: Eric Swayze, Richard H. Griffey, Yili Ding, Venkatraman Mohan
-
Patent number: 6759523Abstract: The present invention is directed to analogs of aminoglycoside compounds of the class having a glycosylated 2-deoxystreptamine (2-DOS) ring as well as their preparation and use as prophylactic or therapeutics against microbial infection. Compounds of the invention comprises at least one aryl, heteroaryl, substituted aryl or substituted heteroaryl group in place of a glycosyl group attached to the 2-deoxystreptamine ring.Type: GrantFiled: November 30, 2000Date of Patent: July 6, 2004Assignee: ISIS Pharmaceuticals, Inc.Inventors: Eric Swayze, Richard H. Griffey, Yili Ding, Venkatraman Mohan
-
Patent number: 6642365Abstract: Conjugates of a saccharide and an acetamidino- or guanidino-compound, of the formula: wherein A is CH3 or NH2; X is a linear or branched C1-C8 alkyl chain optionally containing hydroxy, amino and/or oxo groups; n is an integer from 1 to 6, and Sac is the residue of a mono-or oligo-saccharide, provided that when A is NH2 and X is -(CH2)3—CH(NH2)—C(=O)-, the monosaccharide residue is not substituted at the position 1, and n is an integer from 2 to 6 when Sac is the residue of an oligosaccharide, are useful as antiviral, particularly as antiretroviral, agents, and can be used either alone or together with other compounds used in AIDS treatment such as AZT and/or protease inhibitors, for the treatment of HIV-infection, AIDS and manifestations of AIDS such as Kaposi sarcoma.Type: GrantFiled: June 28, 2001Date of Patent: November 4, 2003Assignee: Yeda Research and Development Co. Ltd.Inventors: Aviva Lapidot, Alexander Litovchick, Artem G. Evdokimov
-
Patent number: 6541456Abstract: The present invention is directed to analogs of aminoglycoside compounds of the class having a glycosylated 2-deoxystreptamine (2-DOS) ring as well as their preparation and use as prophylactic or therapeutics against microbial infection. Compounds of the invention comprises at least one aryl, heteroaryl, substituted aryl or substituted heteroaryl group in place of a glycosyl group attached to the 2-deoxystreptamine ring.Type: GrantFiled: December 1, 1999Date of Patent: April 1, 2003Assignee: ISIS Pharmaceuticals, Inc.Inventors: Eric Swayze, Richard H. Griffey, Yili Ding, Venkatraman Mohan
-
Patent number: 6403777Abstract: Transition metal complexes, referred to hereinafter as “metalloligands”, that catalyze the degradation of DNA and the cleavage of RNA at select sites are provided. In one embodiment, the metalloligand has the following structure: wherein R1 is an amino group, i.e. an NH, or an alkylamino group comprising 1 or 2 carbon atoms; wherein R2 is selected from the group consisting of an amino group, a hydroxyl group, i.e., O(H), an alkylamino group comprising 1 or 2 carbon atoms; and an alkylhydroxyl group comprising 1 or 2 carbon atoms; wherein J is a ligand which comprises at least one carbon-containing five-membered or six-membered ring structure; and wherein M is a transition metal ion which is bound via coordinate bonds to R1 and R2.Type: GrantFiled: July 6, 1999Date of Patent: June 11, 2002Assignee: The Ohio State University Research FoundationInventor: James A. Cowan
-
Patent number: RE44778Abstract: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids) or a member of a class of compounds termed BACAs (Benzyl Amino Carboxylic Acids).Type: GrantFiled: May 30, 2012Date of Patent: February 25, 2014Assignee: Glycomimetics, Inc.Inventors: John L. Magnani, John T. Patton, Jr., Arun K. Sarkar, Sergei A. Svarovsky, Beat Ernst